Lab Anim Res.  2022 Dec;38(4):294-301. 10.1186/s42826-022-00141-4.

Key factors to establish the ovalbumininduced atopic dermatitis minipig model: age and body weight

Affiliations
  • 1Animal Model Research Group, Korea Institute of Toxicology, 30 Baekhak1-gil, 56212 Jeongeup, Jellabuk-do, Republic of Korea
  • 2Department of Medical IT Convergence, Kumoh National Institute of Technology, 39177 Gumi, Gyeongbuk, Korea
  • 3Human Health Risk Assessment Center, Korea Institute of Toxicology, 30 Baekhak1-gil, 56212 Jeongeup, Jellabuk-do, Republic of Korea
  • 4Center for Companion Animal New Drug Development, Korea Institute of Toxicology, 30 Baekhak1-gil, 56212 Jeongeup, Jellabuk-do, Republic of Korea

Abstract

Background
Given its similar structure and immune response to the human skin, porcine is a good model for dermal studies. Here, we sensitized ovalbumin (Ova) on minipig back skin for 2–4 weeks to induce chronic atopic dermatitis (AD).
Results
Gross observation, serum cytokine level, epidermal thickness, and epidermal integrity did not change after 4 weeks of Ova induction compared with the control, indicating AD modeling failure. Only the neutrophils in the blood and macrophages in bronchoalveolar lavage fluid changed slightly until 3 or 2 weeks after Ova sensitization, respectively. The successful and failed Ova-induced AD minipig models only differ in age and body weight of the minipigs. The minipigs, 12 months old with a 30-kg median weight, had a two-fold thicker dermis than minipigs 8–10 months old, with an 18.97-kg median weight, resulting in impaired Ova permeability and immune response.
Conclusion
Age and body weight are key factors that should be considered when developing an Ova-induced AD minipig model.

Keyword

Yucatan minipig; Atopic dermatitis; Ovalbumin; Age/body weight; Dermal thickness
Full Text Links
  • LAR
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr